Teva's Vitiligo Breakthrough
Teva Advances Quarterly-Dosed Anti-IL-15 Antibody to Phase 2b for Vitiligo
Teva Pharmaceutical Industries is preparing to move its experimental vitiligo drug TEV-'408 into a larger Phase 2b trial, targeting a late 2026 launch date The Province. The drug, an anti-interleukin-15 antibody designed for once-quarterly dosing, showed promising early results in patients with non-segmental vitiligo (NSV) — a condition that causes patchy loss of skin color.
At week 24 of the Phase 1b study, nearly 75% of patients reported improvement in facial vitiligo Woodstock Sentinel Review. Half of those patients described their improvement as "much" or "very much" improved. Teva plans to discuss the data on an investor call and live webcast on January 7, 2026.
What TEV-'408 Does and How It Works
Interleukin-15, or IL-15, is a protein that drives immune system activity. In vitiligo, the immune system attacks the cells that give skin its color. TEV-'408 is designed to block IL-15 and slow that attack Ontario Farmer.
A key feature of the drug is its dosing schedule. Most biologics require weekly or monthly injections. TEV-'408 is designed to be given just once every three months. That could be a major convenience advantage if the drug reaches approval Market Screener.
Phase 1b Results Show Skin Pigmentation Gains
The Phase 1b trial enrolled patients with both active and stable NSV. The study measured changes in skin pigmentation over 24 weeks Woodstock Sentinel Review. Both groups showed improvement, suggesting the drug may work regardless of whether the disease is currently spreading.
Nearly 75% of patients reported facial improvement at the 24-week mark The Province. Half described their results as "much" or "very much" improved. Teva has not yet released full data, including specific repigmentation scores, ahead of the January investor webcast.
Phase 2b Trial Planned for Q4 2026
Teva plans to start the Phase 2b study in the fourth quarter of 2026 Market Screener. A Phase 2b trial is larger than Phase 1b and is designed to confirm whether the drug works and at what dose. It typically involves hundreds of patients across multiple sites.
Vitiligo is a growing area for drug developers. The FDA approved Pfizer's Opzelura — the first vitiligo treatment in decades — in 2022. Teva entering the space with a quarterly-dosed antibody could offer a different option for patients who prefer injections over daily creams Ontario Farmer.
Teva to Brief Investors on January 7, 2026
Teva (NYSE: TEVA) will hold an investor call and live webcast on January 7, 2026 to walk through the Phase 1b data Woodstock Sentinel Review. The company has not yet disclosed the full dataset, including safety details or specific repigmentation measurements.
TEV-'408 is part of Teva's push to build a pipeline beyond its generics business. The company has faced financial pressure in recent years. A successful vitiligo drug could be a meaningful addition to its branded portfolio The Province.
Sentiment
NeutralPublishers
4
Articles
4
Reach
4
